VTVT on Nasdaq

vTv Therapeutics Inc.

We are a late-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and inflammatory diseases with the goal of improving patient outcomes.6 From its latest annual report

$28.09 up 0.57 (2.07%)Price as of Oct 15, 2026 at 17:33 UTC

Last updated Oct 19, 2026.

Overview

$0Revenue, fiscal 20254
-$27.0MNet income, fiscal 20254

Compare with 60 DEGREES PHARMACEUTICALS, INC., Dare Bioscience, Inc. or Galena Biopharma, or pick any stock.

  • TickerVTVT on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersHigh Point, United States2
  • Incorporated inDE5
  • Business address3980 Premier Dr, Suite 310, High Point, Nc 272655
  • Filer categoryNon-accelerated filer, Smaller reporting company5
  • Legal formCorporation2
  • LEI549300WQE5EI9R35SE662
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 57180822

See how the biggest companies compare on our leaderboards

We are a late-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and inflammatory diseases with the goal of improving patient outcomes. Our lead product candidate, cadisegliatin (TTP399) , is a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated in a Phase 3 clinical trial as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). The Cadisegliatin as Adjunctive Therapy to Insulin in Participants with Type 1 Diabetes ("CATT1") Phase 3 clinical trial is a randomized, double-blind, placebo-controlled trial designed to evaluate the effect of cadisegliatin on hypoglycemia outcomes in patients with T1D. The primary endpoint is the reduction in the frequency of Level 2 hypoglycemia (blood glucose <54 mg/dL) and Level 3 (severe) hypoglycemia over a six-month treatment perio…6 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-100.0%Revenue growth, 20254
-41.9%Return on equity4

Financial statements

Revenue78910114$0 in 2025
0$5.0M$10.0M$15.0M2018: $12.4M$12.4M20182019: $2.8M$2.8M2019−78%2020: $6.4M$6.4M2020+132%2021: $4.0M$4.0M2021−38%2022: $2.0M$2.0M2022−50%2023: $0$020232024: $1.0M$1.0M20242025: $0$02025
Operating income78910114-$32.8M in 2025+65% since 2018
-$40.0M-$30.0M-$20.0M-$10.0M02018: -$19.8M-$19.8M20182019: -$20.9M-$20.9M2019+5%2020: -$11.9M-$11.9M2020−43%2021: -$21.7M-$21.7M2021+83%2022: -$22.5M-$22.5M2022+4%2023: -$25.5M-$25.5M2023+13%2024: -$24.2M-$24.2M2024−5%2025: -$32.8M-$32.8M2025+36%
Net income78910114-$27.0M in 2025+241% since 2018
-$30.0M-$20.0M-$10.0M02018: -$7.9M-$7.9M20182019: -$13.0M-$13.0M2019+65%2020: -$8.5M-$8.5M2020−35%2021: -$13.0M-$13.0M2021+53%2022: -$19.2M-$19.2M2022+48%2023: -$20.2M-$20.2M2023+6%2024: -$18.5M-$18.5M2024−9%2025: -$27.0M-$27.0M2025+46%

Every line of the income statement as filed: the last 3 fiscal years, latest first.4

Period ending2025-12-312024-12-312023-12-31
Revenue$0$1.0M$0
Research and development$17.9M$11.5M$13.6M
General and administrative$14.9M$13.7M$11.9M
Total operating expenses$32.8M$25.2M$25.5M
Operating loss-$32.8M-$24.2M-$25.5M
Interest income$1.9M$1.6M$472.0K
Interest expense-$6.0K$0-$13.0K
Loss before income taxes and noncontrolling interest-$31.1M-$22.6M-$26.0M
Income tax provision$0$100.0K$0
Net loss before noncontrolling interest-$31.1M-$22.7M-$26.0M
Net loss attributable to noncontrolling interest-$4.1M-$4.2M-$5.7M
Net loss attributable to vTv Therapeutics Inc.-$27.0M-$18.5M-$20.2M
Net loss attributable to vTv Therapeutics Inc. common shareholders-$27.0M-$18.5M-$20.2M

Compare vTv Therapeutics Inc. with another company

Leadership

Who has led vTv Therapeutics Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Stephen L. Holcombe2015–2020
  2. Deepa Prasad2021
  3. Rich S. Nelson2022
  4. Paul J. Sekhri2022–now

Chair

  1. Jeffrey B. Kindler2015–2019
  2. Paul J. Sekhri2024–now

President

  1. Stephen L. Holcombe2015–2020
  2. Deepa Prasad2021
  3. Paul J. Sekhri2022–2024

Chief financial officer

  1. Rudy Howard2015–2020
  2. Steven L. Tuch2022–2024
20202025
Board members and other officers (25)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorJohn A. Fry named Mar 7, 202447

Timeline

  1. Aug 8, 2022New chief executive Paul J. Sekhri becomes CEO19
  2. Mar 4, 2022New chief executive Rich S. Nelson becomes CEO18
  3. Oct 21, 2021New chief executive Deepa Prasad becomes CEO20
  4. Jul 30, 2015New chief executive Stephen L. Holcombe becomes CEO21

Filings

205 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 73 major events, 68 insider forms, 18 large holders, 1 private raises, 24 other. The latest 20:

  1. Oct 8, 2026SCHEDULE 13G/A EDGAR
  2. Oct 6, 20268-K EDGAR
  3. Aug 6, 202610-Q EDGAR
  4. Aug 6, 20268-K EDGAR
  5. Jul 29, 2026SCHEDULE 13G/A EDGAR
  6. Jun 29, 20264 EDGAR
  7. Jun 29, 20268-K EDGAR
  8. Jun 29, 20264 EDGAR
  9. Jun 29, 20264 EDGAR
  10. Jun 29, 20264 EDGAR
  11. Jun 29, 20264 EDGAR
  12. Jun 10, 2026DEFA14A EDGAR
  13. May 13, 202610-Q EDGAR
  14. May 13, 20268-K EDGAR
  15. May 13, 2026424B2 EDGAR
  16. May 13, 20268-K EDGAR
  17. May 13, 2026S-8 EDGAR
  18. Apr 28, 2026DEF 14A EDGAR
  19. Apr 16, 2026SCHEDULE 13G/A EDGAR
  20. Mar 27, 2026SCHEDULE 13G EDGAR

The 205 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

5 open-market trades by officers, directors and large owners since October 2021: 4 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 18, 2024SEKHRI PAUL JPres, CEO and Exec ChairpersonBuy1,844$16.96$31.3KForm 4
Nov 15, 2024SEKHRI PAUL JPres, CEO and Exec ChairpersonBuy3,156$16.65$52.5KForm 4
Nov 29, 2022FRY JOHN ADirectorBuy40,461$0.83$33.6KForm 4
Nov 28, 2022FRY JOHN ADirectorBuy20,539$0.83$17.0KForm 4
Dec 20, 2021PERELMAN RONALD O10% ownerSale87,000$1.15$100.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Feb 27, 2024Raised $51 million in a private offering of equity Form D: 4 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 45. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Samsara Biocapital, LLC298,496$11.2M0.9%No change
Millennium Management LLC269,874$10.2M0.0%+63,586
Fmr LLC260,391$9.8M0.0%No change
Siren, L.L.C.163,000$6.1M0.1%No change
Baker Bros. Advisors LP148,314$5.6M0.0%No change
Vanguard Capital Management LLC94,463$3.6M0.0%−14,459
Trails Edge Capital Partners, LP85,192$3.2M0.5%−54,386
Aisling Capital Management LP50,000$1.9M0.4%New
Marshall Wace, Llp39,560$1.5M0.0%+26,171
Geode Capital Management, LLC32,470$1.2M0.0%−416
Renaissance Technologies LLC17,454$657.1K0.0%New
Vanguard Fiduciary Trust Co16,239$611.4K0.0%+113
BlackRock, Inc.14,731$554.6K0.0%+2,129
Jane Street Group, LLC13,703$515.9K0.0%New
State Street Corp12,266$461.8K0.0%+1,600
Two Sigma Investments, LP11,486$432.4K0.0%New
Verdad Advisers, LP8,996$338.7K0.3%New
Integrated Quantitative Investments LLC8,210$309.1K0.1%New
Susquehanna International Group, Llp8,023$302.1K0.0%New
Quadrature Capital Ltd6,305$237.4K0.0%New
Trexquant Investment LP6,240$234.9K0.0%New
Northern Trust Corp6,123$230.5K0.0%−11,929
Pathstone Holdings, LLC6,073$228.7K0.0%No change
Point72 Asset Management, L.P.5,947$223.9K0.0%New
Citadel Advisors LLC5,906$222.4K0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
    Yahoo FinanceVTVT quote
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56